Skip to main content

Table 2 Liver enzymes and adverse events after 12 weeks of ART

From: Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole

Parameters

Group A (n = 81)

Group B (n = 41)

p value

Liver enzymes

   

ALP at week 12, U/l, median (IQR)

81.5 (65.0–116.8)

77.0 (112.0–132.5)

0.011

AST at week 12, U/l, median (IQR)

20.3 (25.0–33.8)

22.0 (27.5–44.3)

0.351

ALT at week 12, U/l, median (IQR)

17.0 (25.0–38.8)

22.0 (26.0–46.0)

0.329

TB at week 12, mg/dl, median (IQR)

0.3 (0.4–0.5)

0.3 (0.4–0.5)

0.907

Adverse events

   

Skin rashes

6 (7.4%)

0 (0%)

0.096

Clinical hepatitis

0 (0%)*

1 (2.4%)

0.336

  1. * add 0.5 to calculate p value